Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Oracle Corporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Oracle Corporation trades at $127.8 (market cap $434.11B). The key difference: Oracle Corporation is far larger — about 446.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Oracle Corporation pays a 1.4% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Oracle Corporation for 73 Days on average.
| MRVI | ORCL | |
|---|---|---|
Market Cap | $972.90M | $434.11B |
Volume | 4,325,710 | 25,917,551 |
Sector | Health | Technology |
52-Week High | $9.00 | $313.00 |
52-Week Low | $2.83 | $114.99 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $1.08B | $557.92B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Oracle (ORCL) trades at $137.40, down 2.92% on the day amid a bearish technical signal, though it has consistently beaten earnings estimates in recent quarters. Revenue grew to $57.40B in 2025 with a net income margin of 26.36%, while analyst consensus remains strongly bullish with a $236.52 price target. Recent news highlights strong AI cloud demand and restructuring efforts to support growth.
The outlook is positive given robust fundamentals and AI-driven revenue acceleration, but risks include high debt levels, competitive pressures, and market volatility. The stock presents a long-term opportunity if execution on AI infrastructure continues, though near-term price weakness reflects investor caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
